Luke Andrews
Luke Andrews is a health reporter for DailyMail.com with an interest in data-led stories. He holds a master's degree in journalism from City, University of London and has previously written for The Times (UK), Daily Express, Manchester Evening News and North News and Pictures. His reporting covers various topics related to health.
72%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
100%
Examples:
No current examples available.
Conflicts of Interest
50%
Examples:
- The articles do not provide any clear evidence of conflicts of interest for Luke Andrews.
Contradictions
100%
Examples:
No current examples available.
Deceptions
60%
Examples:
- In the article 'Texas bodybuilder, 35, suffers from heart failure after drinking ice cold WATER: Liquid kept hitting nerve at back of his throat and triggering underlying condition', the title is misleading as it suggests that drinking cold water directly causes heart failure. However, the article states that the man had a pre-existing condition called atrial fibrillation, which was triggered by swallowing cold water.
Recent Articles
CDC Recommends Doxycycline as Post-Exposure Prophylaxis Against STIs: A Game Changer in Sexual Health
Broke On: Tuesday, 04 June 2024The CDC recommends using doxycycline as a post-exposure prophylaxis against bacterial STIs for men who have sex with men and transgender women, reducing chlamydia, syphilis, and gonorrhea infections by over 70%, 70%, and approximately 50% respectively. This is the first time doxycycline has been used prophylactically against STIs. The CDC emphasizes this as part of a comprehensive sexual health approach, encouraging risk reduction counseling, STI screening and treatment, recommended vaccination, and linkage to HIV PrEP or other services. 
New Study Finds Semaglutide Improves Taste Sensitivity in Women with Obesity: Implications for Weight Loss
Broke On: Monday, 03 June 2024New research suggests semaglutide, an active ingredient in Ozempic and Wegovy, enhances taste sensitivity in women with obesity. By modifying gene expression and renewing taste buds, semaglutide may reduce cravings for unhealthy foods and aid weight loss. However, potential side effects include dysgeusia. 
GLP-1 Agonists and Gastroparesis: Uncovering the Connection and Its Implications
Broke On: Monday, 20 May 2024Weight loss drugs, such as GLP-1 agonists like Ozempic and Wegovy, have been linked to an increased risk of gastroparesis. Studies suggest that 10 out of every 10,000 people taking these medications for weight loss are diagnosed with gastroparesis at least six months later compared to 4 out of every 10,000 people not taking the medication. Over fifty lawsuits have been filed against drug manufacturers due to potential side effects and lack of clear warnings about this risk. 
How Cold Water Triggered Atrial Fibrillation in Houston Man's Heart and Led to Multiple Hospitalizations
Broke On: Monday, 26 February 2024A man's habit of drinking cold water during workouts led to a fatal heart condition. He suffered from atrial fibrillation, an irregular and dangerous rhythm caused by the vagus nerve reacting to the cold water. He had no idea he was at risk until his last hospitalization, when doctors explained his diagnosis and surgery. 
Unraveling the Genetic Secrets of Disease Risk: The All of Us Research Program's Discovery
Broke On: Tuesday, 20 February 2024A Pulitzer award-winning journalist writes a factual article about the All of Us Research Program, a large-scale study that collects genetic data from diverse participants and discovers new DNA variants linked to disease risk. 
Early Detection of Alzheimer's with ALZpath Dx Blood Test: A Gamechanger for Early Intervention and Treatment
Broke On: Tuesday, 23 January 2024A new blood test called ALZpath Dx can detect Alzheimer's disease up to 15 years before symptoms appear, potentially allowing for earlier intervention and treatment. The test is just as accurate as current gold-standard methods of diagnosis and has the potential to be a gamechanger for early detection and treatment of Alzheimer's. 
Combining PDE5is and Nitrates Increases Risk of Health Outcomes in Men with Cardiovascular Disease
Broke On: Tuesday, 16 January 2024A recent study published in the Journal of the American College of Cardiology found that taking phosphodiesterase type 5 inhibitors (PDE5is) along with nitrates for chest pain medication may increase the risk of negative health outcomes such as heart failure and early death in men with cardiovascular disease. Despite existing research and clinical guidelines discouraging simultaneous use of these medications, physicians are seeing an increase in requests for erectile dysfunction drugs from men with cardiovascular diseases.